Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hologic (HOLX)
NASDAQ:HOLX
Holding HOLX?
Track your performance easily
HOLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$66.93 - $84.67
Previous Close$79.29
Volume1.22M
Average Volume (3M)1.47M
Market Cap
$18.42B
Enterprise Value$18.54B
Total Cash (Recent Filing)$2.44B
Total Debt (Recent Filing)$2.56B
Price to Earnings (P/E)23.9
Beta0.51
Next Earnings
Jan 29, 2025EPS Estimate
$1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.32
Shares Outstanding232,271,906
10 Day Avg. Volume1,889,508
30 Day Avg. Volume1,466,605
Standard Deviation0.09
R-Squared0.30
Alpha0.00100
Financial Highlights & Ratios
Price to Book (P/B)3.72
Price to Sales (P/S)4.69
Price to Cash Flow (P/CF)11.50
P/FCF Ratio11.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.60
Enterprise Value/Gross Profit8.95
Enterprise Value/Ebitda77.82
Forecast
1Y Price Target
$88.60Price Target Upside12.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Hologic News
Bulls Say, Bears Say
Bulls Say
Acquisition And ExpansionThe acquisition of Gynesonics adds a complementary solution for uterine fibroid treatment to the GYN Surgical portfolio, expanding the product offering with minimally invasive tools like the Sonata System.
Financial PerformanceHOLX delivered strong organic growth excluding COVID impacts, driven by diversified strength across molecular diagnostics, women's health, and surgical franchises, with improvements in gross and operating margins.
Product And InnovationThe Panther install base and new assays, particularly in sexual health, are key growth drivers, with the vaginitis test poised to become the largest assay outside of COVID and respiratory testing.
Bears Say
Guidance And Financial PerformanceFY25 guidance below consensus due to headwinds from Skeletal Health disruption and hurricane impact.
Revenue And Earnings EstimatesThe FY25 guidance is potentially conservative as it includes multiple headwinds, including continued supplier-related issues and conservatism in respiratory diagnostics.
Supplier And Supply Chain IssuesOngoing headwinds from supplier-related shipping delays are affecting the skeletal business.
---
Ownership Overview
1.37% Insiders
29.75% Mutual Funds
6.58% Other Institutional Investors
36.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOLX FAQ
What was Hologic’s price range in the past 12 months?
Hologic lowest stock price was $66.93 and its highest was $84.67 in the past 12 months.
What is Hologic’s market cap?
Currently, no data Available
When is Hologic’s upcoming earnings report date?
Hologic’s upcoming earnings report date is Jan 29, 2025 which is in 81 days.
How were Hologic’s earnings last quarter?
Hologic released its earnings results on Nov 04, 2024. The company reported $1.01 earnings per share for the quarter, missing the consensus estimate of $1.013 by -$0.003.
Is Hologic overvalued?
According to Wall Street analysts Hologic’s price is currently Undervalued.
Does Hologic pay dividends?
Hologic does not currently pay dividends.
What is Hologic’s EPS estimate?
Hologic’s EPS estimate is $1.02.
How many shares outstanding does Hologic have?
Hologic has 232,271,910 shares outstanding.
What happened to Hologic’s price movement after its last earnings report?
Hologic reported an EPS of $1.01 in its last earnings report, missing expectations of $1.013. Following the earnings report the stock price went down -5.877%.
Which hedge fund is a major shareholder of Hologic?
Among the largest hedge funds holding Hologic’s share is Bridgewater Associates, LP. It holds Hologic’s shares valued at 24M.
---
Hologic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$88.60 (12.49% Upside)
$88.60 (12.49% Upside)
Blogger Sentiment
Bullish
HOLX Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 132.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.97%
12-Months-Change
Fundamentals
Return on Equity
15.56%
Trailing 12-Months
Asset Growth
0.18%
Trailing 12-Months
Company Description
Hologic
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.
---
HOLX Earnings Call
Q4 2024
0:00 / 0:00
---
HOLX Revenue Breakdown
46.65% Diagnostics
35.55% Breast Health
14.99% GYN Surgical
2.81% Skeletal Health
---
HOLX Stock 12 Month Forecast
Average Price Target
$88.60
▲(12.49% Upside)
Technical Analysis
Best Analysts Covering HOLX
1 Year
1 Year Success Rate
13/19 ratings generated profit
1 Year Average Return
+4.49%
reiterated a buy rating 5 days ago
Copying Puneet Souda's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +4.49% per trade.
---